{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:10Z","timestamp":1793061310535,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacasi.2026.07.019","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:19:51Z","timestamp":1787804391000},"page":"2362-2373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Oncologic Benefits and Cardiovascular Risks of Pembrolizumab"],"prefix":"10.1016","volume":"6","author":[{"given":"Chan Soon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yebin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soongu","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Min","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-3955","authenticated-orcid":false,"given":"Heesun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Kwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungdo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4053-8713","authenticated-orcid":false,"given":"Jun-Bean","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2026.07.019_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jacasi.2026.07.019_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jacasi.2026.07.019_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib8","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib9","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1200\/JCO-24-02786","article-title":"Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2024.3","volume":"43","author":"Leighl","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.22.00503","article-title":"Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Korde","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib11","doi-asserted-by":"crossref","first-page":"H751","DOI":"10.1152\/ajpheart.00378.2023","article-title":"Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications","volume":"325","author":"Banerjee","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib13","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.07.019_bib14","article-title":"The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer","volume":"611","author":"Chiang","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jacasi.2026.07.019_bib15","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2026.07.019_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4070\/kcj.2020.0171","article-title":"Cardiovascular research using the Korean national health information database","volume":"50","author":"Choi","year":"2020","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacasi.2026.07.019_bib18","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.23.02366","article-title":"Cancer treatment disparities in people with HIV in the United States, 2001-2019","volume":"42","author":"McGee-Avila","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jacasi.2026.07.019_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/d41573-021-00022-w","article-title":"The most successful oncology drug portfolios of the past decade","volume":"20","author":"Paliouras","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacasi.2026.07.019_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacasi.2026.07.019_bib23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib24","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jacasi.2026.07.019_bib26","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.07.019_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jacasi.2026.07.019_bib28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib29","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.07.019_bib30","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacasi.2026.07.019_bib31","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.07.019_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726006113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726006113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:21:26Z","timestamp":1793060486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726006113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2772374726006113"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.07.019","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncologic Benefits and Cardiovascular Risks of Pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}